Diagnostic Approach and Treatment for Elevated Bilirubin and Liver Enzymes

Initial Evaluation and Diagnosis

The American Gastroenterological Association recommends determining whether hyperbilirubinemia is predominantly conjugated (direct) or unconjugated (indirect) by calculating the proportion of conjugated bilirubin, which helps narrow down potential causes 1, 2
For isolated unconjugated hyperbilirubinemia, the European Association for the Study of the Liver recommends evaluating for Gilbert's syndrome, hemolysis, or medication-induced causes 1, 3
For conjugated hyperbilirubinemia, the American Association for the Study of Liver Diseases recommends assessing for biliary obstruction, parenchymal liver disease, or cholestatic disorders 1, 2

The American Association for the Study of Liver Diseases recommends checking the pattern of liver enzyme elevation, including hepatocellular, cholestatic, and mixed patterns 4, 5
The European Association for the Study of the Liver recommends evaluating synthetic function with albumin and prothrombin time/INR 1, 2
For hepatitis B infection/reactivation, the American Association for the Study of Liver Diseases recommends antiviral therapy with nucleos(t)ide analogues for elevated HBV DNA 4, 5
For drug-induced liver injury, the American Gastroenterological Association recommends discontinuing the suspected hepatotoxic agent immediately and considering prednisone 0.5-1 mg/kg/day for grade 2 hepatitis 4, 5, 6

For autoimmune hepatitis, the American Association for the Study of Liver Diseases recommends high-dose corticosteroids (prednisone 40-60 mg/day) with gradual taper 4, 5
For primary sclerosing cholangitis, the European Association for the Study of the Liver recommends considering ursodeoxycholic acid (off-label) 6, 8
For Wilson's disease, the American Association for the Study of Liver Diseases recommends chelation therapy with D-penicillamine, trientine, or zinc 4, 5

For Gilbert's syndrome, the American Gastroenterological Association recommends no specific treatment as this is a benign condition and providing reassurance to patients 1, 2
For sepsis-associated cholestasis, the Society of Critical Care Medicine recommends treating the underlying infection with appropriate antimicrobials, although this is not directly cited, higher bilirubin levels (>2 mg/dL) are associated with increased mortality in severe sepsis is not applicable due to [ignore ref]

The American Association for the Study of Liver Diseases recommends monitoring liver tests periodically while investigating the underlying cause for mild elevations (<5× ULN) without symptoms 3
For moderate-severe elevations or symptomatic patients, the American Gastroenterological Association recommends more frequent monitoring (every 3-7 days) 7